These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 27640152

  • 1. Onabotulinumtoxin-A treatment in Greek patients with chronic migraine.
    Vikelis M, Argyriou AA, Dermitzakis EV, Spingos KC, Mitsikostas DD.
    J Headache Pain; 2016 Dec; 17(1):84. PubMed ID: 27640152
    [Abstract] [Full Text] [Related]

  • 2. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC.
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [Abstract] [Full Text] [Related]

  • 3. Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment.
    Vikelis M, Argyriou AA, Dermitzakis EV, Spingos KC, Makris N, Kararizou E.
    J Headache Pain; 2018 Sep 17; 19(1):87. PubMed ID: 30225735
    [Abstract] [Full Text] [Related]

  • 4. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun 17; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 5. Onabotulinumtoxin-A in Chronic Migraine: Should Timing and Definition of Non-Responder Status Be Revised? Suggestions From a Real-Life Italian Multicenter Experience.
    Vernieri F, Paolucci M, Altamura C, Pasqualetti P, Mastrangelo V, Pierangeli G, Cevoli S, D'Amico D, Grazzi L.
    Headache; 2019 Sep 17; 59(8):1300-1309. PubMed ID: 31454075
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Onabotulinumtoxin A (BOTOX®) for ProphylaCTIC Treatment of Pediatric Migraine: A Retrospective Longitudinal Analysis.
    Shah S, Calderon MD, Wu W, Grant J, Rinehart J.
    J Child Neurol; 2018 Aug 17; 33(9):580-586. PubMed ID: 29877131
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Sequential administration of peripheral nerve blocks and onabotulinumtoxinA for the treatment of chronic migraine and other headache disorders-A retrospective tolerability and safety study.
    Anderson CC, Iser CR, Hirte IL, Boddu S, Girardo ME, VanderPluym JH, Starling AJ.
    Headache; 2024 Jun 17; 64(6):663-673. PubMed ID: 38700250
    [Abstract] [Full Text] [Related]

  • 11. Botulinum toxin type A and acute drug costs in migraine with triptan overuse.
    Christie SN, Giammarco R, Gawel M, Mackie G, Gladstone J, Becker WJ.
    Can J Neurol Sci; 2010 Sep 17; 37(5):588-94. PubMed ID: 21059503
    [Abstract] [Full Text] [Related]

  • 12. OnabotulinumtoxinA for the prophylactic treatment of headaches in adult patients with chronic migraine: a safety evaluation.
    Cheng F, Ahmed F.
    Expert Opin Drug Saf; 2021 Nov 17; 20(11):1275-1289. PubMed ID: 34187265
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group.
    Silberstein S, Mathew N, Saper J, Jenkins S.
    Headache; 2000 Jun 17; 40(6):445-50. PubMed ID: 10849039
    [Abstract] [Full Text] [Related]

  • 15. A single-center retrospective study of onabotulinumtoxinA for treatment of 245 chronic migraine patients: survey results of a real-world experience.
    Yalinay Dikmen P, Kosak S, Ilgaz Aydinlar E, Sagduyu Kocaman A.
    Acta Neurol Belg; 2018 Sep 17; 118(3):475-484. PubMed ID: 29992442
    [Abstract] [Full Text] [Related]

  • 16. OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study.
    Domínguez C, Pozo-Rosich P, Torres-Ferrús M, Hernández-Beltrán N, Jurado-Cobo C, González-Oria C, Santos S, Monzón MJ, Latorre G, Álvaro LC, Gago A, Gallego M, Medrano V, Huerta M, García-Alhama J, Belvís R, Leira Y, Leira R.
    Eur J Neurol; 2018 Feb 17; 25(2):411-416. PubMed ID: 29171146
    [Abstract] [Full Text] [Related]

  • 17. Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic migraine.
    Bratbak DF, Nordgård S, Stovner LJ, Linde M, Dodick DW, Aschehoug I, Folvik M, Tronvik E.
    Cephalalgia; 2017 Apr 17; 37(4):356-364. PubMed ID: 27154997
    [Abstract] [Full Text] [Related]

  • 18. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group.
    Headache; 2010 Jun 17; 50(6):921-36. PubMed ID: 20487038
    [Abstract] [Full Text] [Related]

  • 19. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study.
    Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM.
    Otolaryngol Head Neck Surg; 2000 Dec 17; 123(6):669-76. PubMed ID: 11112955
    [Abstract] [Full Text] [Related]

  • 20. Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year.
    Aicua-Rapun I, Martínez-Velasco E, Rojo A, Hernando A, Ruiz M, Carreres A, Porqueres E, Herrero S, Iglesias F, Guerrero AL.
    J Headache Pain; 2016 Dec 17; 17(1):112. PubMed ID: 27957623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.